PMID: 8581387Oct 1, 1995Paper

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu

Journal of Hematotherapy
F H ValoneJ Fisher

Abstract

MDX-210 is a bispecific antibody (BsAb) that recognizes Fc gamma R1 on monocytes and macrophages and the cell surface product of the HER-2/neu oncogene, which is overexpressed on some breast and ovarian cancers. Clinical trials have demonstrated that treatment with MDX-210 is well tolerated and that MDX-210 is both immunologically and clinically active. Optimization of the dose and schedule of MDX-210 and development of combination treatments with cytokines that modulate immune effector cells will greatly enhance the efficacy of this novel BsAb construct for treatment of tumours that overexpress HER-2/neu. We envision that MDX-210 will be effective for treating patients with tumors that overexpress HER-2/neu, especially in the minimal disease setting.

References

Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A E MaluishR G Steis

❮ Previous
Next ❯

Citations

Jan 19, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Philippe Fournier, Volker Schirrmacher
Nov 1, 2003·Biochemical and Biophysical Research Communications·Zhigang XieNing Guo
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
May 7, 1999·International Journal of Immunopharmacology·J W Hadden
Dec 16, 1998·Research in Immunology·C A Guyre, M W Fanger
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F RévillionJ P Peyrat
Oct 6, 1999·Current Opinion in Immunology·D M SegalL M Weiner
Feb 15, 1997·Medizinische Klinik·F Hartmann, M Pfreundschuh
May 31, 2006·Cancer Immunology, Immunotherapy : CII·D RitchieH M Prince
Aug 1, 2000·Immunology Today·A B van SprielJ G van De Winkel
Jan 13, 2006·Cancer Metastasis Reviews·Jeffrey S RossNeil H Bander
Jul 25, 2008·European Journal of Immunology·Fernanda V V CastroMartin J Glennie
Apr 28, 2004·Trends in Biotechnology·Peter KuferPatrick A Baeuerle
Feb 1, 1997·Journal of Chemotherapy·E A TorreR A Fulco
Apr 26, 2005·Methods : a Companion to Methods in Enzymology·Partha S Chowdhury, Herren Wu
Jan 26, 2008·Nature Reviews. Cancer·Jason RiceFreda K Stevenson
May 15, 2007·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Nicolas Fischer, Olivier Léger
Oct 1, 1996·Journal of Hematotherapy·A DwengerR Mertelsmann
Jul 1, 2010·Expert Review of Clinical Pharmacology·Jijie Gu, Tariq Ghayur
May 22, 2020·Journal of Drug Targeting·Vala KafilYadollah Omidi
Sep 19, 2017·AIDS Research and Human Retroviruses·David MerriamDennis J Hartigan-O'Connor
Nov 17, 1998·Bioconjugate Chemistry·Y Cao, M R Suresh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.